Best Practices and Research Advances in Thoracic Oncology: A Regional Series SE Asia Course 3: Driver Alterations in Lung Cancer-Targeted Therapies in Advanced Disease

Video Transcription

Video Summary

Dr. Junko Tanizaki from Kindai University discusses targeted therapies for advanced lung cancer, focusing on EGFR and HER2 mutations. Targeted therapies offer potential long-term survival benefits but are less likely to be curative compared to immune checkpoint inhibitors. EGFR mutations, especially exon 19 deletion and L858R, comprise a significant portion of lung cancer cases, notably higher in East Asians. Osimertinib is a preferred first-line treatment based on the FLORA trial results. Recent advancements include FLORA2 and myripoza studies, showcasing combinations like osimertinib with platinum-based chemotherapy and amivantamab with lazertinib, respectively, which improve progression-free survival (PFS).<br /><br />For EGFR exon 20 insertions and HER2 mutations, emerging treatments like amivantamab and trastuzumab deruxtecan show promise, alongside novel TKIs under phase 3 evaluation. Despite advances, consideration of treatment toxicity and regional applicability remains crucial. Continued research is essential to refine resistance management and optimize second-line treatments.

Asset Subtitle

Junko Tanizaki, MD, PhD

Keywords

targeted therapies

EGFR mutations

osimertinib

HER2 mutations

lung cancer